2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-16734A
    Amiselimod hydrochloride 942398-84-7 98.86%
    Amiselimod (MT-1303) hydrochloride is converted to its active metabolite Amiselimod phosphate by sphingosine kinases in vivo. Amiselimod hydrochloride is an orally active and high selectivity sphingosine 1-phosphate receptor-1 (S1P1) agonist, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators. Amiselimod hydrochloride inhibits chronic colitis via inhibiting infiltration of colitogenic Th1 and Th17 cells into the colon. Amiselimod hydrochloride inhibits lupus nephritis by reducing the infiltration of autoreactive T cells into the kidneys. Amiselimod hydrochloride is promising for research of autoimmune diseases.
    Amiselimod hydrochloride
  • HY-P0018B
    Pepstatin Ammonium 99.76%
    Pepstatin (Pepstatin A) Ammonium is a specific, orally active aspartic protease inhibitor produced by actinomycetes, with IC50s of 4.5 nM, 6.2 nM, 150 nM, 290 nM, 520 nM and 260 nM for hemoglobin-pepsin, hemoglobin-proctase, casein-pepsin, casein-proctase, casein-acid protease and hemoglobin-acid protease, respectively. Pepstatin Ammonium also inhibits HIV protease.
    Pepstatin Ammonium
  • HY-B1157
    Trioxsalen 3902-71-4 99.49%
    Trioxsalen (Trisoralen), a psoralen derivative, is a photochemical DNA crosslinker. Trioxsalen only works after photoactivation with near ultraviolet light. Trioxsalen is a photosensitizer that can be used for the research of vitiligo and hand eczema. Trioxsalen is used for visualization of genomic interstrand cross-links localized by laser photoactivation.
    Trioxsalen
  • HY-114371
    Eclitasertib 2125450-76-0 99.80%
    Eclitasertib (DNL-758) is a potent receptor-interacting protein kinase 1 (RIPK1) inhibitor with an IC50 of 0.0375 µΜ.
    Eclitasertib
  • HY-116835
    BI-6901 2040401-92-9 99.76%
    BI 6901 is a potent, selective CCR10 antagonist (pIC50=9.0). BI 6901 shows high selectivity over other GPCRs, including a number of other chemokine receptors. BI 6901 is efficacious in the murine DNFB model of contact hypersensitivity and can be used for inflammation research.
    BI-6901
  • HY-139612
    Opnurasib 2653994-08-0 98.20%
    Opnurasib (JDQ-443) (NVP-JDQ443) is an orally active, potent, selective, and covalent KRAS G12C inhibitor. Opnurasib shows antitumor activity.
    Opnurasib
  • HY-16992A
    W-54011 405098-33-1 99.57%
    W-54011 is a potent and orally active non-peptide C5a receptor antagonist. W-54011 inhibits the binding of 125I-labeled C5a to human neutrophils with a Ki value of 2.2 nM. W-54011 also inhibits C5a-induced intracellular Ca2+ mobilization, chemotaxis, and generation of ROS in human neutrophils with IC50s of 3.1 nM, 2.7 nM, and 1.6 nM, respectively.
    W-54011
  • HY-B0288B
    Fenoprofen Calcium hydrate 71720-56-4 99.52%
    Fenoprofen (LILLY-53858) Calcium hydrate is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits cyclooxygenase (COX). Fenoprofen Calcium hydrate is a melanocortin receptors (MCRs) positive allosteric modulator (PAM). Fenoprofen Calcium hydrate also increases ERK1/2 activation in HEK293T cells. Fenoprofen Calcium hydrate has anti-arthritic activities and can be used for the study of rheumatoid arthritis and osteoarthritis.
    Fenoprofen Calcium hydrate
  • HY-P99322
    Tesidolumab 1531594-08-7
    Tesidolumab (LFG316) is a fully-human IgG1/λ anti-C5 monoclonal antibody of 143 kDa (without glycosylation). Tesidolumab (LFG316) blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex.
    Tesidolumab
  • HY-P99378
    Neihulizumab 2158362-38-8 98.97%
    Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research.
    Neihulizumab
  • HY-P99414
    Prezalumab 1523164-68-2 ≥99.0%
    Prezalumab (AMG 557) is a humanized IgG2 monoclonal antibody targeting ICOSL. Prezalumab inhibits T cell activation and related immune responses by binding to ICOSL and blocking the interaction between ICOS and ICOSL. Prezalumab can be used in the research of autoimmune diseases and inflammatory diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
    Prezalumab
  • HY-P99430
    Alnuctamab 2296827-07-9 99.89%
    Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and CD3, belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA expressed on the surface of myeloma cells and CD3 molecules on the surface of T cells, recruiting T cells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Alnuctamab
  • HY-101364A
    CHPG sodium salt 1303993-73-8 99.57%
    CHPG sodium salt is a selective mGluR5 agonist, and attenuates SO2-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells. CHPG sodium salt protects against traumatic brain injury (TBI) in vitro and in vivo by activation of the ERK and Akt signaling pathways..
    CHPG sodium salt
  • HY-P2476
    Peripheral Myelin P0 Protein (180-199), mouse 147450-30-4 99.84%
    Peripheral Myelin P0 Protein (180-199), mouse, a neuritogenic peptide, is a purified component of murine peripheral nerve myelin.
    Peripheral Myelin P0 Protein (180-199), mouse
  • HY-P2518
    Protease-Activated Receptor-1, PAR-1 Agonist 141136-85-8 99.70%
    Protease-Activated Receptor-1, PAR-1 Agonist is a selective proteinase-activated receptor1 (PAR-1) agonist peptide. Protease-Activated Receptor-1, PAR-1 Agonist corresponds to PAR1 tethered ligand and which can selectively mimic theactions of thrombin via this receptor.
    Protease-Activated Receptor-1, PAR-1 Agonist
  • HY-10404
    Dilmapimod 444606-18-2 99.56%
    Dilmapimod (SB-681323) is a potent p38 MAPK inhibitor that potentially suppresses inflammation in chronic obstructive pulmonary disease.
    Dilmapimod
  • HY-10418
    AH 6809 33458-93-4 99.57%
    AH 6809 is an antagonist of EP and DP receptor, with Kis of 1217, 1150, 1597, and 1415 nM for the cloned human EP1, EP2, EP3-III, and DP receptor respectively. AH 6809 has a Ki of 350 nM for mouse EP2 receptor.
    AH 6809
  • HY-13568
    Benoxaprofen 51234-28-7 ≥98.0%
    Benoxaprofen (LRCL 3794) is a nonsteroidal anti-inflammatory agent that blocks the biosynthesis of inflammatory mediators such as leukotrienes and prostaglandins by inhibiting 5-LOX, PGH2 synthase and cytochrome P-450. Benoxaprofen exhibits significant toxicity: it not only alters cellular redox status, uncouples oxidative phosphorylation and disrupts calcium ion homeostasis, but also causes liver injury through the formation of covalent adducts between its active metabolites and hepatic proteins. Benoxaprofen shows strong phototoxicity under ultraviolet irradiation, and induces erythrocyte lysis, mast cell degranulation and histamine release. Benoxaprofen is widely used in studies of urticaria and related phototoxic mechanisms.
    Benoxaprofen
  • HY-15039
    SSR240612 464930-42-5 98.72%
    SSR240612 is a potent, and orally active specific non-peptide bradykinin B1 receptor antagonist, with Kis of 0.48 nM and 0.73 nM for B1 kinin receptors of human fibroblast MRC5 and HEK cells expressing human B1 receptors, 481 nM and 358 nM for B2 receptors of guinea pig ileum membranes and CHO cells expressing human B1 receptor, respectively.
    SSR240612
  • HY-19326
    SU1498 168835-82-3 98.84%
    SU1498 (AG 1498) is a selective inhibitor of the VEGFR2; inhibits Flk-1 with an IC50 of value of 700 nM.
    SU1498
Cat. No. Product Name / Synonyms Application Reactivity